Is Apellis Pharmaceuticals, Inc. (APLS) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 18.5% / 30% | 18.2% / 30% | 14.4% / 30% | 1.31% / 5% | ✓ HALAL |
| DJIM | 18.5% / 33% | 18.2% / 33% | 14.4% / 33% | 1.31% / 5% | ✓ HALAL |
| MSCI | 44.1% / 33% | 43.4% / 33% | 34.3% / 33% | 1.31% / 5% | ✗ NOT HALAL |
| S&P | 18.5% / 33% | 18.2% / 33% | 14.4% / 33% | 1.31% / 5% | ✓ HALAL |
| FTSE | 44.1% / 33% | 43.4% / 33% | 34.3% / 50% | 1.31% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 60.3% | |
| Operating Margin | -25.6% | |
| Net Margin | 2.2% | |
| Return on Equity (ROE) | 7.5% | |
| Return on Assets (ROA) | 3.5% |
Cash Flow & Balance Sheet
| Operating Cash Flow | $45M |
| Free Cash Flow | $45M |
| Total Debt | $474M |
| Debt-to-Equity | 128.2 |
| Current Ratio | 3.1 |
| Total Assets | $1.1B |
Price & Trading
| Last Close | $17.64 |
| 50-Day MA | $20.75 |
| 200-Day MA | $22.44 |
| Avg Volume | 2.8M |
| Beta | 0.3 |
|
52-Week Range
$16.10
| |
About Apellis Pharmaceuticals, Inc. (APLS)
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops EMPAVELI to treat C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, focal segmental glomerulosclerosis, and delayed graft function; and APL-3007, a small interfering RNA, or siRNA for the treatment of GA. In addition, it conducts preclinical studies for APL-9099, a treatment targeting the neonatal Fc receptor, or FcRn, which has the potential to be a first-in-class gene editing treatment for future target indications with one-time dosing; and developing other programs with its proprietary in-house capabilities and under its Beam collaboration. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics, Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. Apellis Pharmaceuticals, Inc. was incorporated in 2009 and is headquartered in Waltham, Massachusetts.
Purification Calculator
As a halal stock with 1.31% impermissible income, you need to purify your dividends.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Apellis Pharmaceuticals, Inc. (APLS) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Apellis Pharmaceuticals, Inc. is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Apellis Pharmaceuticals, Inc.'s debt ratio?
Apellis Pharmaceuticals, Inc.'s debt ratio is 18.5% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 44.1%.
Does Apellis Pharmaceuticals, Inc. require dividend purification?
Yes, Apellis Pharmaceuticals, Inc. has an impermissible income ratio of 1.31%, which means 1.31% of any dividends received should be donated to charity as purification. This is because a small portion of the company's revenue comes from non-Shariah-compliant sources.
What are Apellis Pharmaceuticals, Inc.'s key financial metrics?
Apellis Pharmaceuticals, Inc. has a market capitalization of $2.2B, trailing P/E ratio of 94.3, and revenue of $1.0B. The company maintains a gross margin of 60.3% and a net margin of 2.2%. Return on equity stands at 7.5%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.